 |
市場調查報告書
商品編碼
1983289
骨髓發育不良症候群治療市場：依藥物、給藥途徑、通路及地區分類Myelodysplastic Syndrome Treatment Market, By Drug, By Route Of Administration, By Distribution Channel, By Geography |
||||||
2026年骨髓發育不良症候群治療市場規模估計為29.9億美元，預計到2033年將達到46.3億美元。預計2026年至2033年，該市場將以6.4%的複合年成長率成長。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 29.9億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 6.40% | 預計金額（2033 年） | 46.3億美元 |
骨髓發育不良症候群)是一組癌症，其特徵是骨髓中未成熟的血球無法成熟並分化為正常血球。不同類型的骨髓發育不良症候群是根據血球和骨髓的特定變化進行診斷的。骨髓發育不良症候群(MDS) 是一種罕見的癌症，其特徵是正常血球生成不足。它也被稱為骨髓增生異常綜合症。 MDS 有多種類型。在 MDS 中，骨髓中的一些細胞異常（發育不良），難以產生新的血球。這些骨髓細胞形成的一些血球有缺陷。這些缺陷細胞通常比正常細胞死亡得更快，而且身體還會破壞一些異常血細胞，因此患者體內剩餘的正常血球不足。雖然多種類型的細胞都可能受到影響，但骨髓發育不良症候群最常見的觀察是紅血球缺乏（貧血）。治療相關性 MDS 是骨髓發育不良症候群的一種類型。這是由於既往癌症治療中的化療或放射線治療所致。在美國，骨髓發育不良症候群的新病例和治療相關性骨髓發育不良症候群的病例都在增加。這主要是由於人口老化程度的提高以及癌症治療後生存期的延長。
市場動態
Azacitidine在北美、拉丁美洲、歐洲、亞太和非洲等主要地區的上市和核准不斷增加，預計將在預測期內推動骨髓骨髓發育不良症候群治療市場中Azacitidine細分市場的成長。例如，2018年2月，生技公司百濟神州宣佈在中國推出維達茲（Azacitidine注射液）。維達茲已在中國獲準用於治療中危險/高風險第2型骨髓發育不良症候群（MDS）、急性骨髓性白血病（AML）以及慢性粒單核細胞白血病（CMML）。該產品由百濟神州在中國核准，並獲得新基公司（一家製藥公司）的獨家授權。
本報告的主要特點
- 本報告指出了各個細分市場的潛在商機，並概述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本文根據以下參數，介紹了全球骨髓發育不良症候群(MDS) 治療市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球骨髓發育不良症候群(MDS) 治療市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球骨髓發育不良症候群(MDS) 治療市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 法規環境
- 產品上市及核准
- PEST分析
- 波特的分析
- 市場機遇
- 法規環境
- 主要進展
- 產業趨勢
第4章：全球骨髓發育不良症候群治療市場：按藥物分類（2020-2033 年）
- Lenalidomide
- Decitabine
- Azacitidine
- 處於 III 期臨床實驗階段的藥物
第5章：全球骨髓發育不良症候群治療市場：依給藥途徑分類（2020-2033 年）
- 注射
- 口服
第6章：全球骨髓發育不良症候群治療市場：依通路分類（2020-2033 年）
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球骨髓發育不良症候群治療市場：按地區分類（2020-2033 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第8章 競爭情勢
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
第9章 分析師建議
- 機會
- 分析師意見
- Coherent Opportunity Map (COM)
第10章：參考文獻與分析方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
Myelodysplastic Syndrome Treatment Market is estimated to be valued at USD 2.99 Bn in 2026 and is expected to reach USD 4.63 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.99 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.40% | 2033 Value Projection: | USD 4.63 Bn |
Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer.
Market Dynamics
Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company).
Key features of the study
- This report provides an in-depth analysis of the global myelodysplastic syndrome (MDS) treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myelodysplastic syndrome (MDS) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myelodysplastic syndrome (MDS) treatment market
Market Segmentation
- Drug Insights (Revenue, USD Bn, 2026 - 2033)
- Lenalidomide
- Decitabine
- Azacitidine
- Phase 3 Drugs
- Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
- Injection
- Oral
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Myelodysplastic Syndrome Treatment Market, By Drug
- Global Myelodysplastic Syndrome Treatment Market, By Route of Administration
- Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel
- Global Myelodysplastic Syndrome Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Myelodysplastic Syndrome Treatment Market, By Drug, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Lenalidomide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Decitabine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Azacitidine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Phase 3 Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
5. Global Myelodysplastic Syndrome Treatment Market, By Route of Administration, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global Myelodysplastic Syndrome Treatment Market, By Distribution Channel, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
7. Global Myelodysplastic Syndrome Treatment Market, By Region, 2020 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acceleron Pharma, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aprea Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FibroGen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Onconova Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Geron
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
